Interferon (IFN)-free, direct-acting antiviral (DAA) therapy agents provide a safe and efficacious treatment for liver transplant recipients with recurrent hepatitis C virus (HCV) infection. The aim of this study is to evaluate the impact of HCV eradication on the metabolic factors in liver transplant recipients. We completed a retrospective single-center study on HCV-related liver transplant recipients treated with IFN-free DAAs including both treatment-naive and treatment-experienced patients. IFNfree DAAs impact on the metabolic profile were assessed at baseline and sustained virological response (SVR) between 24 and 48 weeks. In total, 91 liver transplant recipients with recurrent HCV infection received IFN-free DAA treatment, 62 patients had IFN-based treatment failure, and 29 were treatment-naïve, of whom 87 (96%) achieved SVR. Eradication of recurrent HCV infection was associated with reduction in the treatment of diabetes and hypertension by 38% and 22% from the baseline respectively. Hemoglobin A1c (HbA1c) levels declined from mean 35.5 ± 4.3 mmol/mol to 33.3 ±3.6 mmol/mol at 44 weeks posttreatment (P = 0.03). Total cholesterol levels increased from 3.8 ± 0.9 mmol/L to 4.9 ± 0.9 mmol/L at 41 weeks posttreatment (P < 0.0001), reflecting a significant increase in serum low-density lipoprotein (LDL) levels (2.0 ± 0.8 to 2.9 ± 0.8; P < 0.0001). Estimated glomerular filtration rate (eGFR) levels increased from 64.9 ± 20 mL/minute to 69.6 ± 20 mL/minute at 24 weeks posttreatment (P = 0.0004). Glucose, lipid profile, and eGFR changes were independent of weight changes and immunosuppression dosage and trough levels. In conclusion, eradication of recurrent HCV infection by DAA therapy has beneficial impacts on glucose metabolism and renal profile and reverses the hypolipidemic effect of HCV in liver transplant recipients. These extrahepatic effects of DAA therapy need to be validated by larger prospective studies. 
people, and it is now the leading cause of liver-related mortality and liver transplantation. (1) Although widespread access of safe and effective direct-acting antiviral (DAA) therapies is salvaging many patients with HCVrelated decompensated cirrhosis, the number listed for HCV-related hepatocellular carcinoma is expected to increase steadily for at least the next 10 years. (2, 3) Several epidemiological studies have described an association between chronic HCV infection and increased incidence and rate of progression of insulin resistance and diabetes mellitus. (4) (5) (6) (7) Experimental models suggest that HCV may impair insulin sensitivity either directly through induction of both hepatocyte and peripheral insulin resistance mediated either by direct viral effects or indirectly due to suppression of adiponectin expression and suppressor of cytokine signaling 3 (SOCS-3) activation induced by the production of proinflammatory cytokines like interleukin (IL) 6. (8) Also, in patients with cirrhosis, insulin resistance may be caused by reduced clearance of insulin through portosystemic shunting, decreased hepatic extraction secondary to liver synthetic failure, and hyperinsulinemia due to increased serum glucagon levels. (8) (9) (10) Chronic HCV infection has also been associated with hypolipidemia. Circulating cholesterol and very low density lipoprotein (VLDL) levels fall in chronic HCV infection secondary to both down-regulation of de novo cholesterol synthesis through reduction in geranyl pyrophosphate (an intermediate substrate for mevalonate pathway) and increased utilization for HCV membrane formation. Depletion of intracellular cholesterol will upregulate low-density lipoprotein (LDL) receptors and decrease circulating LDL levels providing evidence of a direct interaction between HCV infection and host lipid metabolism. (11, 12) Despite these hypolipidemic effects, the various other multiple metabolic effects of HCV may contribute to the reported increase in cardiovascular morbidity and mortality in patients with chronic HCV infection. (13, 14) This association between HCV and diabetes mellitus has also been observed following liver transplantation for HCV-related diseases, when recurrence of hepatitis C virus (HCV) infection is universal. The prevalence of posttransplant diabetes mellitus at 1-year posttransplant was more than five-fold higher in transplant recipients with recurrent HCV infection than those without, thereby contributing to the posttransplant metabolic syndrome (PTMS). (8, 15, 16) PTMS is associated with accelerated fibrosis progression and will impact the longterm outcomes in liver transplant recipients with recurrent HCV infection. (8, 17, 18) Sustained HCV suppression can halt liver disease progression and prevent both liver-related and extrahepatic complications. (19) (20) (21) (22) HCV suppression should also prevent or reverse the direct metabolic effects of HCV. In an important proof-of-concept study, 14 days of treatment with danoprevir, a potent NS3/4A protease inhibitor, significantly improved insulin sensitivity, with a direct correlation between reduction of HCV RNA level and decrease in homeostasis model assessment of insulin resistance (HOMA-IR). Cessation of danoprevir was followed by rapid rebound of both HCV RNA and HOMA-IR to baseline levels. (23) Subsequent studies have demonstrated sustained improvement in insulin sensitivity and diabetic control following HCV eradication following both interferon (IFN)-based and IFN-free antiviral therapy. (24) (25) (26) (27) This current study determines the effect of successful DAA treatment on glycemic control, blood pressure, lipid profile, and renal functions in posttransplant HCV recipients.
Patients and Methods
All adults transplanted for either HCV-related decompensated cirrhosis or hepatocellular carcinoma at the New Zealand Transplant Unit between December 1998 and December 2016 were included. Retrospective review of clinical records was conducted to identify baseline patient demographic (ethnicity, age, gender), virology (HCV genotype and viremia level) and stages of liver disease (fibrosis stage based on recent available posttransplant biopsy using METAVIR scoring and fibro-scan F1 ≥ 7 KPa; F2 = 8-9 KPa; F3 = 9-14Kpa; F4 > 14Kpa). The type of antiviral therapy and outcome was recorded. The presence of treatment for hyperlipidemia, hypertension and diabetes mellitus was recorded before and after antiviral therapy at 24 to 48 weeks after sustained virus response (SVR). Presence of diabetes, hypertension, and hyperlipidemia was established by looking at community dispensing records through the Test Safe network and clinical follow-up letters.
The impact of new IFN-free therapy on diabetes, hypertension, and lipid profile were evaluated in patients with liver transplantation performed between December 1998 and December 2014 from the study date June 2017. The eligible patients had new IFN-free therapy completion duration more than 3 months and were on "stable immunosuppression" prior to the commencement of new IFN-free treatment. Stable immunosuppression was defined as patients with steroid cessation for more than 3 months and had no antirejection medication dosage change for more than 3 months.
The effect on the prevalence of diabetes and hypertension with new IFN-free treatment among the eligible ORIGINAL ARTICLE | 1033 cohort was estimated by the proportion of recipients who had a reduction or cessation of hypoglycemic and antihypertensive treatment at SVR between 24 and 48 weeks after treatment completion. The effect on glucose and lipid metabolism was measured by change in hemoglobin A1c (HbA1c) and lipid levels before and after completion of antiviral therapy (SVR between 24 and 48 weeks). Mean HbA1c, blood glucose levels, and lipid profile metabolic parameters were measured within 24 months from the start of new IFN-free treatment and between 24 and 48 weeks after viral therapy completion. Patients cured prior to liver transplant and posttransplant recipients with less than 12 weeks of viral therapy completion were excluded from the analysis.
The impact of HCV treatment on renal function in liver transplant recipients was determined by (1) the proportion of recipients with estimated glomerular filtration rate (eGFR) <60 mL/minute before and between 24 to 48 weeks after HCV treatment and (2) the change in eGFR between baseline and beyond 24 and 48 weeks posttreatment. Patients on renal replacement therapy were excluded from the analysis to study the impact on the eGFR.
IFN-free treatment effect on immunosuppression was assessed by measuring mean tacrolimus trough levels and dosage within 3 months before treatment commencement, during, and 24 weeks posttreatment completion. Also, body mass index (BMI) was recorded before and after treatment.
statistiCal analYsis
Continuous and categorical data were reported as mean ± standard deviation (SD)/median (interquartile range [IQR] ) and percentage, respectively. Paired t test and one-way analysis of variance was used to analyze the continuous data based on parametric distribution of data. Linear regression was also used to analyze continuous data. A generalized estimating equation (GEE) performed the test of trends on multiple measurements per individual with robust measurement of variant (β-coefficient). A two-tailed P value < 0.05 was considered statistically significant. Data analysis was performed by using Prism Graph Pad 7 and R programming language.
Results
A total of 153 adults underwent liver transplantation for either HCV-related decompensated cirrhosis or hepatocellular carcinoma between December 1998 and December 2016. A total of 132 (86%) received posttransplant antiviral therapy for recurrent HCV infection, of whom 81% were male and 81% European ethnicity. The median age at the time of HCV treatment was 58 years (IRQ , 52-62 years). The median time interval between transplant and antiviral treatment was 4 years (IRQ , 2-8 years). Sixty-eight patients (51.5%) had genotype GT1 infection; 6 (4.5%) had GT2; 53 (40%) had GT3; 3 (2%) had GT4; and 1 each had GT5 and GT6 infection (Table 1) .
Initial immunosuppression following liver transplantation was tacrolimus plus steroids in all patients. At the time of antiviral therapy, 83% were maintained on tacrolimus monotherapy whilst the remaining 17% had been switched to mycophenolate plus prednisone (usually for chronic renal impairment). No patients were maintained on mammalian target of rapamycin (mTOR) inhibitors.
A total of 103 transplant recipients (67%) received at least one course of IFN-based treatment, of whom 24 (23%) achieved SVR. Among them, 14 patients were cured post-liver transplantation and had treatment at a mean duration of 3 ± 1.5 year after transplantation. A total of 91 transplant recipients (69%) received IFNfree DAA treatment, including 62 patients who had failed previous IFN-based treatment. Tolerability of IFN-free DAA treatment was excellent and all patients completed treatment and follow-up. A total of 87 (96%) achieved SVR, the remaining 4 patients all relapsed between 4 and 12 weeks posttreatment (Fig. 1) . Most patients received sofosbuvir-based treatment (SOF-RBV in 19, LDV-SOF in 55, SOF-VEL in 5; Table 2 ).
iMpaCt On tHE MEtaBOliC DisEasE prEvalEnCE anD CHrOniC KiDnEY DisEasE
A total of 64 liver transplant recipients met the eligibility criteria to study the impact of posttransplant DAA therapy on the prevalence of diabetes, hypertension and chronic kidney disease (CKD). Before antiviral therapy, 26 (41%) patients were established on diabetic treatment (24 on insulin alone, 2 on insulin plus oral hypoglycemic therapy). Following successful antiviral therapy, only 16 (25%) were still maintained on any hypoglycemic treatment corresponding with the 40% reduction of diabetes treatment from the baseline. Insulin requirements fell from median 37 IU (IRQ , 35-71; 95% CI, 35-85) to 32 IU (IRQ , 22-54.5; 95% CI, 20-55; P = 0.005) in those patients who continued on insulin. Before antiviral therapy, 23 (36%) patients were receiving antihypertensive treatment. Following successful antiviral therapy, only 14 (22%) patients were still maintained on antihypertensive treatment. Moreover, the patients with eGFR <60 mL/minute reduced by 46%. Observed improvements in metabolic control and renal function were greater in patients infected with HCV GT 1 than in those infected with other genotypes (Table 3) . Of post-liver transplant patients cured with IFN-based treatment, diabetes and hypertension prevalence did not change, but there was a drop in insulin requirement (Table 4) .
iMpaCt On GlUCOsE, lipiD prOFilE anD eGFr
A total of 38 liver transplant recipients were not taking diabetic medications at the time of antiviral therapy. The mean plasma glucose level in these 38 patients decreased by 1.1 mmol/L at 24 weeks after DAA treatment (6.8 ± 1.7 versus 5.7 ± 1.1 mmol/L, P = 0.01). Nineteen patients had paired HbA1c data available before and after DAA treatment. Plasma HbA1c levels declined from mean 35.5 ± 4.3 mmol/mol (95% CI, 33.4-37.5) at baseline to 33.3 ±3.6 mmol/mol (95% CI, 31.6-36.5) at 44 weeks after SVR (P = 0.03; Fig. 2A ). NOTE: Data are given as n (%). *Nine patients on sofosbuvir + ribavarin + peginterferon (PEG) were excluded from the analysis to study the metabolic prevalence and metabolic profile impact.
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Thirty-five liver transplant recipients were not receiving lipid-lowering medication at the time of antiviral therapy. Significant changes in lipid profile were observed at 41 weeks after SVR, with increases in total serum cholesterol level (3.8 ± 0.9 mmol/L [95% CI, 3.5-4.1] to 4.9 ± 0.9 mmol/L [95% CI, 4.5-5.2]; P < 0.0001; Fig. 2B ) and serum LDL level (2 ± 0.08 mmol/L [95% CI, 1.7-2.3] to 2.9 ± 0.8 mmol/L [95% CI, 2.6-3.2]; P < 0.0001; Fig. 2C ). In contrast, serum HDL levels (1. Significant improvements in renal function were observed: eGFR increased from 64.9 ± 20 mL/minute (95% CI, 60-70) prior to therapy to 69.6 ± 20 mL/ minute (95% CI, 65.7-74.6) at 24 weeks after SVR (P = 0.0004; Fig. 2F ).
Changes in HbA1c and the lipid profile were similar in patients cured with IFN and those cured with DAAs (Table 4) .
iMpaCt OF antirEJECtiOn iMMUnOsUpprEssiOn anD BMi
At IFN-free treatment start, median tacrolimus trough level was 6.4 (IRQ , 5.4-7.9; 95% CI, 5.8-7.2), decreased to 5.4 (IRQ , 4.4-6.2; 95% CI, 4.8-5.8) on treatment, and maintained more or less the same levels 5.3 (IRQ, 4.8-6.5; 95% CI, 5-6) during 24 weeks after treatment completion (P = 0.0004). Mean tacrolimus dosage requirement at baseline was 2.05 ± 1 mg (95% CI, 1.6-2.3), increased to 2.64 ± 1.27 mg (95% CI, 2.2-3.0) on the treatment, and 2.45 ± 1.27 mg (95% CI, 2.04-2.85) during 24 weeks after treatment completion (P = 0.07).
Considering tacrolimus trough values before the IFN treatment as a baseline, the decrease in tacrolimus had no relationship with dosage (Fig. 3) .
BMI before and after IFN-free treatment was 28.3 ± 4.9 kg/m 2 (95% CI, 26.9-29.7) and 28.8 ± 5.3 kg/m 2 (95% CI, 27.2-30.3), respectively (P = 0.16).
Discussion
This current study demonstrates that DAA therapy is safe and effective for recurrent HCV infection NOTE: Data are given as n (%) or %. ↓= reduction; eGFR <60 mL minute.
following liver transplantation and 97% of participants achieved SVR, including those who had previously failed IFN-based treatment. The results from this real-world experience are consistent with those from the previously published clinical studies. (28, 29) This study also demonstrates that eradication of recurrent hepatitis C is associated with unblocking the hypolipidemic effect of chronic HCV infection and improving glucose and renal function independent of immunosuppression therapy. The increase in total cholesterol and LDL but not in TG and HDL levels following SVR with DAA therapy is consistent with previous observations in nontransplant patients with HCV infections treated with IFN-based therapy and is thought to reflect the role of the intrahepatic cholesterol biosynthetic pathway in the HCV replication cycle. (30) (31) (32) (33) Chronic HCV infection increases the risk of cardiovascular events, (34) and successful eradication with DAA therapy reduces this risk by almost two-thirds. (35) The role of the altered lipid profile on cardiovascular risk profile following SVR remains controversial. However, the amelioration of insulin resistance and restoration of glucose hemostasis following SVR definitely lowers the cardiovascular event risks. (36) (37) (38) The prevalence of metabolic disease is high after liver transplantation. The prevalence of PTMS is 45% to 58% in liver transplant recipients followed for at least 6 months. The prevalence of diabetes increases from 15% before transplant to 30% to 40% after transplant, while 
FiG. 3.
Tacrolimus trough levels (y axis) plotted against tacrolimus doses (x axis). Graph of change in tacrolimus dosage from baseline and change in mean tacrolimus trough levels from baseline during treatment (black dots) and after treatment (red dots). The baseline is taken as the before treatment values. A regression analysis (purple line) was performed by GEE with 95% confidence intervals (purple dashed lines) shown as calculated using robust measures of variance.
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the prevalence of hypertension increases from 15% up to 60% to 70%. Dyslipidemia is uncommon before transplant in patients without biliary cirrhosis but develops in 50% to 70% of liver transplant recipients. The possible factors contributing to the onset of PTMS include obesity, advanced age, and maintenance corticosteroid therapy. (8, (39) (40) (41) Although the adoption of steroid-sparing immunosuppressive regimens has helped reduce the prevalence of PTDM, this has been offset by the direct effects of recurrent HCV infection. (4) (5) (6) (7) (8) 41) A direct causal relationship between recurrent HCV infection and onset of PTDM is supported by evidence that viral eradication leads to restoration of insulin sensitivity, improved diabetic control, and improved renal function. (19, (22) (23) (24) (25) (26) 38) Restoration of insulin sensitivity has been demonstrated in nontransplant patients following HCV eradication with IFN-based therapy. (25) (26) (27) (28) (29) 35) This is the first study to report the favorable effects of DAAs on PTMS in liver transplant patients with recurrent HCV infection. The impact of viral eradication on metabolic parameters was higher among patients infected with HCV GT1 than those infected with HCV GT3 in this study, consistent with other reports, (42, 43) and may reflect genotypic-specific effects on lipid profile and insulin resistance. (43) (44) (45) Renal dysfunction is common following liver transplantation, secondary to the nephrotoxic effects of calineuring inhibitors and other medications. The prevalence of significant renal dysfunction is increased in patients with recurrent HCV infection because of associated immune complex disease and diabetes. (46, 47) The improvements in renal function seen in this study folowing DAA therapy are likely to reflect resolution of immune complex disease and improvement in diabetic control. (38, 48, 49) Several measures were taken to minimize potential confounders of immunosuppression and ongoing metabolic treatment. All patients were on stable antirejection therapy and were steroid free for at least 3 months after liver transplant. Also, to determine the impact of recurrent HCV infection on PTMS, all patients established on hypoglycemic, hypotensive, and hypolipidemic treatment at the time of transplant were excluded. Lastly, only patients with data available at least 24 weeks after treatment were included to measure stable changes rather than transient changes.
Our study showed that metabolic changes in HCVinfected liver transplant recipients were independent of immunosuppression requirements and BMI changes. Metabolic changes manifested despite the increase in immunosuppression treatment. The most likely explanation is due to improved hepatic clearance by increasing hepatic cytochrome P450 3A4 and hepatic P-glycoprotein activity by eliminating the negative effect of inflammatory cytokines with the eradication of HCV infection. (50) There are some limitations in the design of this study. This is a retrospective study, and the small sample size of the study did not allow for studying homogeneity of outcomes, hence the results can be considered hypothesis generating, not generalizable across the disease population. Serial assessments of insulin sensitivity (HOMA-IR) were not available. Renal function assessments were limited to serum creatinine and calculated eGFR. Metabolic improvement correlations with histological improvement following IFNfree therapy were not investigated. Finally, no control group was included as all patients with recurrent HCV were treated with DAAs after these became funded.
In conclusion, increased access to highly effective DAA therapy both before and after liver transplantation should rapidly eradicate recurrent HCV infection in liver transplant recipients. In addition to preventing recurrent cirrhosis and HCV-related graft failure, HCV eradication should also help improve the posttransplant metabolic profile, thereby preventing extrahepatic morbidity and mortality related to cardiovascular and renal disease. Longer follow-up should confirm the improved patient and graft outcomes associated with DAA therapy.
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